Abstract Number: 2477 • 2014 ACR/ARHP Annual Meeting
Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Background/Purpose Physicians, patients, and payers may have different ideas about what constitutes successful treatment and how treatment goals should be defined for rheumatoid arthritis (RA).…Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…Abstract Number: 2396 • 2014 ACR/ARHP Annual Meeting
Treat to Target in Routine Clinical Practice
Background/Purpose: In order to overcome obstacles with overbooked outpatient clinics and lack of capacity to see rheumatoid patients frequently for treatment escalation, we established a…Abstract Number: 2870 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity and Serum Levels Of Angiogenic Factors In Patients With Rheumatoid Arthritis In Clinical Remission With Synovitis On Ultrasound
Background/Purpose: To identify and characterize subclinical synovitis in patients with rheumatoid arthritis in clinical remission using power Doppler ultrasound and serum levels of angiogenic factors.…Abstract Number: 2803 • 2013 ACR/ARHP Annual Meeting
Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being…Abstract Number: 2276 • 2013 ACR/ARHP Annual Meeting
Does Socioeconomic Status Affect Outcomes In Early Rheumatoid Arthritis? Data From An Inception Cohort
Background/Purpose: Assess the impact of socioeconomic status (SES) on outcomes in patients with early inflammatory arthritis using data from the Canadian Early Arthritis Cohort (CATCH)…Abstract Number: 1522 • 2013 ACR/ARHP Annual Meeting
Remission In Spondyloarthritis : ASDAS and Basdai Thresholds From a Prospective Real Life Study
Background/Purpose: Remission is the current target of management of chronic rheumatic diseases. Whereas in rheumatoid arthritis remission criteria have been recently proposed, in spondyloarthritis, no…Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…Abstract Number: 1332 • 2013 ACR/ARHP Annual Meeting
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity To Response To Therapy In Early Rheumatoid Arthritis
Background/Purpose: Obesity per se is a systemic, low-grade inflammatory state and the adipose tissue is an endocrine organ that releases bioactive substances, including pro-inflammatory cytokines,…Abstract Number: 1336 • 2013 ACR/ARHP Annual Meeting
The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Background/Purpose: To elucidate the safety and feasibility of a treat-to-target (T2T) strategy aimed at achieving a simplified disease activity index (SDAI) of ≤3.3 while administering…Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…Abstract Number: 419 • 2013 ACR/ARHP Annual Meeting
A Long Term Observation Of Rheumatoid Arthritis Who Developed Methotrexate Related Lymphoproliferative Disorders
Background/Purpose: Methotrexate (MTX) has been increasingly administered by patients with rheumatoid arthritis (RA). In rare cases, we experience development of malignant lymphoma in patients treated…Abstract Number: 371 • 2012 ACR/ARHP Annual Meeting
Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis
Background/Purpose: Treat-to-target is the consensus treatment strategy for patients with rheumatoid arthritis (RA), but supporting evidence for treat-to-target strategy in elderly RA patients in clinical…Abstract Number: 109 • 2012 ACR/ARHP Annual Meeting
Does Joint Sonography Really Add Clinically Important Information Beyond Clinical Joint Examination?
Background/Purpose: Sonographic assessment of joint activity in patients with rheumatoid arthritis (RA) is considered to be more sensitive than the respective clinical assessment. However, this…Abstract Number: L7 • 2012 ACR/ARHP Annual Meeting
Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial
Background/Purpose: Step-down therapeutic strategies are often considered in established rheumatoid arthritis (RA) once remission is achieved but are associated with a potential risk of relapse…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- Next Page »